Craig Eagle - 13 Dec 2023 Form 4 Insider Report for Guardant Health, Inc. (GH)

Reporting relationship: Chief Medical Officer
Issuer ticker: GH
Reported as of: 13 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Dec 2023, 17:20:41 UTC
Prior SEC filing: 02 Oct 2023
Next SEC filing: 03 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ John G. Saia, as attorney-in-fact for Craig Eagle

Key filing fact

Craig Eagle filed Form 4 for Guardant Health, Inc. (GH) on 15 Dec 2023.

Key facts

This page summarizes Craig Eagle's Form 4 filing for Guardant Health, Inc. (GH).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 15 Dec 2023, 17:20.

Change

Previous filing in this sequence was filed on 02 Oct 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GH transaction Derivative

STOCK OPTION (RIGHT TO BUY)

Award

Transaction value: $0
Shares: +29,861
Change %
Price: $0.000000
Shares after: 29,861
Date: 13 Dec 2023
Ownership: Direct
Underlying class: COMMON STOCK
Underlying amount: 29,861
Exercise price: $28.37
Footnotes: F1

GH transaction Derivative

RESTRICTED STOCK UNITS

Award

Transaction value: $0
Shares: +19,907
Change %
Price: $0.000000
Shares after: 19,907
Date: 13 Dec 2023
Ownership: Direct
Underlying class: COMMON STOCK
Underlying amount: 19,907
Exercise price: $0.000000
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This represents a stock option granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vests on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.

Footnote F2

This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vests on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Footnote F3

Not applicable for Restricted Stock Units.